Non-Muscle Invasive Bladder Cancer Therapy (likely nadofaragene firadenovec/Adstiladrin)

About Finvector Vision Therapies

FinVector is a privately held, commercial-stage CDMO and therapeutics company with a core focus on viral vector manufacturing for gene therapies. The company has established itself as an FDA-approved manufacturer, currently producing a commercial gene therapy for bladder cancer, indicating it is revenue-generating. Its business model combines contract manufacturing services with a potential proprietary therapeutic focus, supported by a strong leadership team with ties to Ferring Pharmaceuticals. FinVector's strategic position in the high-growth gene therapy manufacturing sector is bolstered by its modern facility and experienced team.

Therapeutic Areas

Other Non-Muscle Invasive Bladder Cancer Drugs